Skip to content
Homepage
Author:
Apollomics Inc.
Posted Date:
July 13, 2026
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Apollomics Inc.
July 13, 2026
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics Inc.
June 24, 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics Inc.
April 27, 2026
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Inc.
April 1, 2026
